Open AccessSerum levels of chemokines in adolescents with major depression treated with fluoxetine
Author(s) -
Francisco R. de la Peña,
Carlos Cruz-Fuentes,
Lino Palacios,
Manuel Iván Girón-Pérez,
Emilio MedinaRivero,
María Dolores Ponce-Regalado,
Samantha Álvarez-Herrera,
Gilberto PérezSánchez,
Enrique Becerril-Villanueva,
José Luis Maldonado-García,
María Carmen Jiménez-Martínez,
Lenin Pavón
Publication year - 2020
Publication title -
world journal of psychiatry
Language(s) - English
Resource type - Journals
ISSN - 2220-3206
DOI - 10.5498/wjp.v10.i8.175
Subject(s) - chemokine , major depressive disorder , eotaxin , depression (economics) , medicine , fluoxetine , macrophage inflammatory protein , ccl17 , immunology , inflammation , gastroenterology , endocrinology , chemokine receptor , receptor , amygdala , serotonin , economics , macroeconomics
Major depressive disorder (MDD) is a global health issue that affects 350 million people of all ages. Although between 2% and 5.6% of affected individuals are adolescents, research on young patients is limited. The inflammatory response contributes to the onset of depression, and in adult MDD patients, symptom severity has been linked to chemokine levels.